跳至主要内容
临床试验/NCT06478160
NCT06478160招募中不适用

Effectiveness of Closed-blood Sampling Devices in the Adult Critically Ill Patient: Multicenter Randomized Clinical Trial

University of Barcelona3 个研究点 分布在 1 个国家目标入组 216 人开始时间: 2024年11月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
216
试验地点
3
主要终点
Units of red blood cells transfusion

研究概览

简要总结

Based on the hypothesis that the strategy of using Closed-Blood Sampling Devices (CSBD, experimental group) compared to the usual practice (waste discard volume, control group), in critically ill adult patients, will decrease the amount of blood withdrawn for laboratory tests, we want to analyze the number of red blood cells (RBC) administered and arterial catheter-related adverse events (catheter-related bacteremia, catheter obstruction, CBSD malfunction, loss of arterial pressure waveform on the patient's bedside monitor) in both study groups, during ICU stay and up to a maximum of 21 days.

详细描述

When a patient with an arterial catheter completes 24h of admission to the unit, with an expected catheter stay of more than 72 hours, inclusion in the study will be assessed. If the patient does not meet the non-inclusion or exclusion criteria and consents to participate in the study, he/she will be randomized to the CBSD-experimental group or waste discard volume- control group.

If the patient belongs to the CBSD-experimental group, the CBSD will be placed in the arterial line at that moment. All extractions performed will be through the arterial catheter and using the CBSD.

In the waste discard volume- control group, the arterial catheter will also be used for extractions but with the usual open extraction system of the ICU. To quantify the blood loss related to blood collection for laboratory tests, the volume of discharge (VD) used for each analysis through the arterial catheter will be recorded. In the CBSD-experimental group the VD for arterial catheter will be zero since CBSD will always be used. The laboratory tubes extracted in each analysis will also be recorded.

Data on blood analysis, blood transfusion and adverse events related to the arterial catheter will be recorded daily during the ICU stay, up to day 21 maximum and/or day of ICU discharge and/or exitus.

Patients discharged from ICU to hospitalization will be followed only during the first 48h to know if they have received red blood cell concentrates and with what previous Hemoglobine (Hb) and hematocrit (Hto).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

盲法说明

Outcomes Assessor and statistician who analyze the results

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adult patients with an arterial catheter who agree to participate in the study, with a stay in the ICU of 24h and a minimum of 72h more with an arterial catheter
  • •Non-inclusion criteria: Therapeutic Limitation of Life Support, Jehovah's Witnesses.

排除标准

  • •Patients with chronic renal failure
  • •Patients with active gastrointestinal bleeding
  • •Patients diagnosed with hematologic cancer
  • •Women with menstruation at the time of admission
  • •Pregnant women
  • •Withdrawal criteria: presence of active gastrointestinal bleeding during the study inclusion period.

研究组 & 干预措施

CBSD-experimental group

Experimental

blood collection with Closed-Blood Sampling System (CBSD)

干预措施: Closed-Blood Sampling Devices (Device)

Waste discard volume, control group

Active Comparator

Blood collection without CBSD, usual practice, need to waste discard volume

干预措施: Waste discard volume (Other)

结局指标

主要结局

Units of red blood cells transfusion

时间窗: Every day during the ICU stay and up to a maximum of 21 days after randomization (day 0)

Number of red blood cells (RBC) units administered in both study groups

次要结局

  • Number and type of adverse events(Every day during the stay and up to a maximum of 21 days after randomization (day 0):)
  • Volume of blood drawn(Every day during ICU stay and up to a maximum of 21 days after randomization (day 0).)
  • Levels of hemoglobine and hematocrit(Every day during ICU stay and up to a maximum of 21 days after randomization (day 0).)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Marta Raurell-Torreda

Clinical Professor

University of Barcelona

研究点 (3)

Loading locations...

相似试验